Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, and its commercial alcohol metabolism product, unbuzzd(TM). The company is focused on advancing innovative therapies for neurodegenerative and metabolic disorders, as well as alcohol misuse.
Durkacz emphasized that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis (MS) by targeting nerve damage, an area he believes remains unmet by currently available treatments. The drug candidate is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of MS, in preclinical models. Quantum BioPharma is preparing for its upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in MS patients following Phase 1 testing in healthy volunteers. This milestone is crucial for the company as it moves closer to potentially offering a novel therapy for MS patients suffering from mobility impairment.
In addition to its pipeline, Quantum BioPharma highlighted unbuzzd(TM), a commercial product designed to accelerate blood alcohol metabolism and currently available in the U.S. market. The company invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd (as of March 31, 2026) and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. This arrangement provides a recurring revenue stream that supports the company's broader research and development efforts.
The podcast appearance underscores Quantum BioPharma's dual strategy of advancing a high-potential drug candidate while monetizing a commercial product. The Phase 2 trial for Lucid-MS represents a significant catalyst, as positive results could validate its mechanism of action and open a substantial market opportunity in MS treatment. Meanwhile, unbuzzd's growing presence in the U.S. market offers immediate revenue potential and reduces reliance on future clinical successes.
For more information, visit the company's newsroom at https://ibn.fm/QNTM and view the full press release at https://ibn.fm/8sLvp.
